---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088330"
form_type: "8-K"
ticker: null
cik: "0001600132"
company_name: "Bellerophon Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:18:48.149098+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bellerophon CEO Peter Fernandes and VP Parag Shah to depart under separation agreements

## Summary
- CEO Peter Fernandes' separation effective Nov 15, 2023; receives lump sums of $205,950 plus two $102,975 payments.
- VP Parag Shah's separation effective Aug 31, 2023; receives $140,600 upfront and $140,600 later.
- Both will perform transition duties until separation dates and have signed release of claims and non-solicit covenants.
- No successor or interim appointments announced for either departing executive.

## SEC filing metadata
- accession: 0001104659-23-088330
- form_type: 8-K
- cik: 0001600132
- company_name: Bellerophon Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/tm2322999d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088330
- JSON: https://secwatch.observer/filing/0001104659-23-088330.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088330.txt

## Key facts
- Executive change
  Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..
  - Action: separated
  - Role: Chief Executive Officer
  source text: On August 3, 2023, Bellerophon Therapeutics, Inc. (the “Company”) entered into a transition and separation agreement with Peter Fernandes, the Company’s Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm
- Executive change
  Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..
  - Action: separated
  - Role: Vice President of Business Operations
  source text: and a transition and separation agreement with Parag Shah, the Company’s Vice President of Business Operations
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.